60 Degrees Pharmaceuticals, Inc.

SXTP Nasdaq SEC CIK 1946563
Follow 60 Degrees Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $233.2K −46.7% vs same quarter last year
Net income −$2.6M −10.4% vs same quarter last year
EPS, diluted −$0.75 +71.8% vs same quarter last year
Operating cash flow −$1.4M +31.4% vs same quarter last year
Revenue by quarter
$241.6K
$163.6K
$100.9K
$437.6K
$303.4K
$162.1K
$207.9K
$233.2K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−$10M−$7.5M−$5M−$2.5M$0$2.5MFY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1M−$7.4M
FY24$607.6K−$7.9M
FY23$253.6K−$3.8M
FY22$223.2K−$6.2M
FY21--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%1000%FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2522.3%−771.6%−732.5%
FY2436.7%−1599%−1308%
FY23−87.1%−2032.8%−1485.1%
FY22−93.7%−784.2%−2769.5%
FY21---
Free cash flowOperating cash flow minus capital expenditure
−$8M−$6M−$4M−$2M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$7M
FY24−$5.8M
FY23−$4.6M
FY22-
FY21-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • 60 Degrees Pharmaceuticals
  • Healthcare median
−3000%−2000%−1000%0%FY21FY22FY23FY24FY25
Show the numbers
Year60 Degrees PharmaceuticalsHealthcare median
FY25−732.5%−30.6%
FY24−1308%−47%
FY23−1485.1%−58%
FY22−2769.5%−80.4%
FY21-−71.9%